Searchable abstracts of presentations at key conferences in endocrinology

ea0013p228 | Neuroendocrinology and behaviour (including pituitary) | SFEBES2007

The novel broad-spectrum somatostatin receptor agonist SOM230 (Pasireotide), blocks the adrenalectomy-induced increase in mitotic activity in male rat anterior pituitary

Nolan Lesley , Schmid Herbert , Levy Andrew

The novel somatostatin receptor agonist SOM230 (pasireotide) binds with high affinity to somatostatin receptors sst1, sst2, sst3 and sst5. Acting principally through the latter, it inhibits basal and CRH-stimulated ACTH secretion from the AtT20 mouse corticotroph cell line and ACTH release from a proportion of human corticotroph adenomas both in vitro and in vivo. Data suggesting an additional antiproliferative effect has led to SOM230 being explored as a potenti...

ea0016p659 | Signal transduction | ECE2008

Ligand-dependent internalization of somatostatin receptors

van Vugt Harmke H , Schmid Herbert A , Sailer Andreas W

Somatostatin (somatotrophin release inhibiting factor; SRIF) is produced primarily in the hypothalamus and pancreas and inhibits the secretion of many hormones and neurotransmitters. Moreover, SRIF and SRIF analogs are able to inhibit tumor growth. Many human neuroendocrine and non-neuroendocrine tumors express the five known somatostatin receptors (sst1–5) in different amounts.Tachyphylaxis after prolonged treatment with octreotide (Sand...

ea0038p146 | Neoplasia, cancer and late effects | SFEBES2015

The somatostatin analogue pasireotide decreased proliferation and increased apoptosis in pancreatic and pituitary neuroendocrine tumors in a MEN1 mouse model

Stevenson Mark , Walls Gerard , Soukup Ben , Lines Kate , Grossman Ashley , Schmid Herbert , Thakker Rajesh

Improved therapies for pancreatic and pituitary neuroendocrine tumors (NETs), which may occur in Multiple Endocrine Neoplasia type 1 (MEN1), are needed. We assessed the effects of pasireotide, a somatostatin analogue with high affinity for somatostatin receptors (SSTRs) −1, −2, −3 and −5, in a mouse model of MEN1. Men1+/− mice treated from 12 months of age with 40 μg/g pasireotide (n=71), or phosphate-buffered sal...

ea0015p179 | Endocrine tumours and neoplasia | SFEBES2008

Somatostatin analogues stimulate AMPK (AMP-dependent protein kinase), a metabolic enzyme with anti-proliferative effects

Leontiou Chrysanthia A , Schmid Herbert , McSheehy Paul , Grossman Ashley B , Korbonits Marta

Background: AMPK is a metabolic enzyme regulating the energy supply of the cell but it has antiproliferative effects as well via the up-regulation of the p53-p21 axis and inhibition of the mTOR-pathway. Somatostatin (SST) analogues reduce hormone secretion from somatotroph adenomas and tumour growth inhibition can also be achieved. SST affect several signalling pathways including the mTOR-pathway. mTOR is a mediator of a pro-proliferative pathway that can be inhibited by activ...

ea0035p905 | Pituitary Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2014

Effect of pasireotide on GH, IGF1, IGFBP2, IGFBP3, HbA1C and glucose in patients with inadequately controlled acromegaly: exploratory results from a multicentre, randomized, 24-week study (PAOLA)

Schmid Herbert , Brue Thierry , Colao Annamaria , Gadelha Monica , Shimon Ilan , Kapur Karen , D'Amato Lisa , Pedroncelli Alberto , Fleseriu Maria

Background: The PAOLA study assessed the efficacy/safety of pasireotide LAR vs continued treatment with octreotide LAR/lanreotide Autogel in patients with inadequately controlled acromegaly. An exploratory objective was to measure changes in various associated biomarkers, including IGF1 and IGFBP2 (released from white fat cells and known to prevent insulin resistance), glucose and HbA1c.Methods: Adult patients (GH >2.5 μg/l and IGF1 >1.3&#21...

ea0014oc3.1 | Endocrine tumors &amp; neoplasia | ECE2007

Multiple somatostatin receptor subtypes activation reduces cell viability in non-functioning pituitary adenomas by inhibiting Vascular Endothelial Growth Factor secretion

Zatelli Maria Chiara , Piccin Daniela , Tagliati Federico , Ambrosio Maria Rosaria , Bianchi Antonio , Bondanelli Marta , Schmid Herbert A , Scanarini Massimo , Marinis Laura De , Maira Giulio , Uberti Ettore C degli

Somatostatin (SRIF) analogs have been employed in medical therapy of non-functioning pituitary adenomas (NFA), with contrasting results. Previous evidence showed that SRIF can exert its antiproliferative effects by reducing Vascular Endothelial Growth Factor (VEGF) secretion and action, and that VEGF expression may be related to pituitary tumor growth. The aim of our study was to clarify the possible effects of a multireceptor SRIF ligand on VEGF secretion and cell proliferati...

ea0035oc12.2 | Pituitary Basic | ECE2014

Differential in vitro response to octreotide and pasireotide in normal and tumoral primary pituitary cell cultures

Ibanez-Costa Alejandro , Gahete Manuel David , Jimenez-Reina Luis , Rivero-Cortes Esther , Lopez-Sanchez Laura Maria , Galvez Maria Angeles , de la Riva Andres , Benito-Lopez Pedro , Venegas-Moreno Eva , Angel Japon Miguel , Moreno Alberto , Garcia-Arnes Juan Antonio , Maraver-Selfa Silvia , Angel Arraez Miguel , Leal-Cerro Alfonso , Schmid Herbert A. , Tinahones Francisco J. , Soto-Moreno Alfonso , Castano Justo P. , Luque Raul M.

Somatostatin analogs (SSA) are a first-line treatment for pituitary adenomas (PA). Indeed, multi-receptor targeting SSA such as octreotide and pasireotide are being successfully used to control hormone secretion and/or tumor growth. Unfortunately, many PA escape from SSA-therapy, which could be related to somatostatin receptor (sst) presence, abundance, availability and/or signaling. In order to better define the molecular/cellular features associated to octreotide and pasireo...